Elanco Animal Health (ELAN) Expected to Post Quarterly Earnings on Wednesday

Elanco Animal Health (NYSE:ELAN) is anticipated to announce its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Elanco Animal Health to post earnings of $0.2692 per share and revenue of $1.3125 billion for the quarter. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Parties may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:00 AM ET.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.06. The company had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.Elanco Animal Health’s revenue was up 14.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.37 earnings per share. On average, analysts expect Elanco Animal Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Elanco Animal Health Trading Up 0.2%

ELAN opened at $26.42 on Monday. The stock’s fifty day moving average is $24.55 and its two-hundred day moving average is $24.07. The company has a market capitalization of $13.20 billion, a P/E ratio of -52.85, a PEG ratio of 1.72 and a beta of 1.68. Elanco Animal Health has a 52 week low of $13.39 and a 52 week high of $27.72. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60.

Insider Buying and Selling

In related news, CEO Jeffrey N. Simmons bought 4,971 shares of the company’s stock in a transaction dated Friday, May 15th. The shares were acquired at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the transaction, the chief executive officer directly owned 171,971 shares in the company, valued at $3,454,897.39. This trade represents a 2.98% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Rajeev A. Modi acquired 4,911 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was purchased at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the acquisition, the insider owned 160,812 shares in the company, valued at $3,272,524.20. The trade was a 3.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 1.14% of the company’s stock.

Institutional Investors Weigh In On Elanco Animal Health

Large investors have recently modified their holdings of the business. Compound Planning Inc. boosted its position in Elanco Animal Health by 29.7% during the fourth quarter. Compound Planning Inc. now owns 21,312 shares of the company’s stock worth $482,000 after acquiring an additional 4,876 shares during the last quarter. Invesco Ltd. boosted its stake in Elanco Animal Health by 336.0% during the fourth quarter. Invesco Ltd. now owns 4,789,037 shares of the company’s stock worth $108,376,000 after buying an additional 3,690,735 shares during the period. Corient Private Wealth LLC boosted its position in shares of Elanco Animal Health by 122.3% during the 4th quarter. Corient Private Wealth LLC now owns 165,381 shares of the company’s stock worth $3,743,000 after purchasing an additional 90,993 shares during the period. Mercer Global Advisors Inc. ADV boosted its position in shares of Elanco Animal Health by 29.0% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 78,610 shares of the company’s stock worth $1,779,000 after buying an additional 17,657 shares during the period. Finally, State of Tennessee Department of Treasury boosted its holdings in Elanco Animal Health by 8.1% during the 4th quarter. State of Tennessee Department of Treasury now owns 146,658 shares of the company’s stock valued at $3,532,000 after acquiring an additional 11,012 shares during the period. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on ELAN shares. JPMorgan Chase & Co. increased their price target on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. TD Cowen boosted their price objective on shares of Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, June 18th. Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. Morgan Stanley increased their price objective on Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a report on Wednesday, July 22nd. Finally, Citigroup increased their price objective on shares of Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $28.73.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.